Skip to main content
SpringerLink
Log in

Concizumab: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

A Correction to this article was published on 03 August 2023

This article has been updated

Abstract

Concizumab (Alhemo™), a subcutaneously administered humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor (TFPI), binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to activated Factor X. Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. This article summarizes the milestones in the development of concizumab leading to this first approval for the treatment of hemophilia B.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

References

  1. Hart DP, Matino D, Astermark J, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022. https://doi.org/10.1177/20406207221085202.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397(10274):630–40.

    Article  CAS  PubMed  Google Scholar 

  3. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.

    Article  PubMed  Google Scholar 

  4. Chowdary P. Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab. Drugs. 2018;78(9):881–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pasca S. Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: a review of the evidence and patient’s perspectives. J Blood Med. 2022;13:191–9.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Novo Nordisk Canada Inc. Concizumab (Alhemo™): Canadian product monograph. 2023. https://www.novonordisk.ca. Accessed 01 May 2023.

  7. Novo Nordisk. Novo Nordisk annual report 2022. 2023. https://www.novonordisk.com. Accessed 01 May 2023.

  8. Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv. 2021;5(1):279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Leissinger C. Another victory for patients with hemophilia. N Engl J Med. 2023;388(4):372–3.

    Article  PubMed  Google Scholar 

  10. Novo Nordisk. Health Canada approves Alhemo™, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors [media release]. 17 April 2023. https://www.novonordisk.ca.

  11. European Medicines Agency. Applications for new human medicines under evaluation by the CHMP. 2023. https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation. Accessed 18 May 2023.

  12. Hilden I, Lauritzen B, Sørensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119(24):5871–8.

    Article  CAS  PubMed  Google Scholar 

  13. Lauritzen B, Hilden I. Concizumab promotes haemostasis via a tissue factor-factor VIIa-dependent mechanism supporting prophylactic treatment of haemophilia: results from a rabbit haemophilia bleeding model. Haemophilia. 2019;25(6):e379–82.

    Article  PubMed  Google Scholar 

  14. Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184–95.

    Article  CAS  PubMed  Google Scholar 

  15. Kjalke M, Kjelgaard-Hansen M, Andersen S, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: in vitro and ex vivo analyses. J Thromb Haemost. 2021;19(7):1687–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lauritzen B, Olling J, Abel KL, et al. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits. J Thromb Haemost. 2019;17(3):460–9.

    Article  PubMed  Google Scholar 

  17. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743–54.

    Article  CAS  PubMed  Google Scholar 

  18. Jimenez Yuste V, Angchaisuksiri P, Castaman G, et al. Concizumab prophylaxis in patients with haemophilia A or B with inhibitors: efficacy and safety results from the primary analysis of the phase 3 explorer7 trial [abstract no. LB 01.2]. Res Pract Thromb Haemost. 2022;6(Suppl 1): e12787.

    Google Scholar 

  19. Novo Nordisk. Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors [media release]. 10 July 2022. https://www.globenewswire.com/.

  20. Frei-Jones M, Cepo K, d’Oiron R, et al. Subcutaneous concizumab prophylaxis in patients with hemophilia A or B with inhibitors: efficacy and safety results by hemophilia subtype from the phase 3 explorer7 trial [abstract no. 191]. Blood. 2022;140(Suppl 1):466–8.

    Article  Google Scholar 

  21. Wheeler AP, Shapiro A, Porstmann T, et al. Risk mitigation during concizumab prophylaxis in phase 3 clinical trials in patients with hemophilia A/B with and without inhibitors: management of breakthrough bleeds and dose optimization [abstract]. Am J Hematol. 2023;98(Suppl 1):E118–9.

    Google Scholar 

  22. Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134(22):1973–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Shapiro AD, Angchaisuksiri P, Astermark J, et al. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022;6(11):3422–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Susan J. Keam

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

The original article has been updated: Due to Figure 1 update.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 503 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keam, S.J. Concizumab: First Approval. Drugs 83, 1053–1059 (2023). https://doi.org/10.1007/s40265-023-01912-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01912-6

Search

Navigation